THOROFARE, N.J., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that the Company's Management System has been certified by SAI Global, a leading global management systems Certification Body, to ISO 13485 (the "Certification"). The Certification is a requirement in certain countries to enable regulatory approval of medical devices.
ISO 13485 is an International Organization for Standardization (ISO) standard, published in 2003, that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.
"Given the Company's strategy to expand sales internationally, achieving this quality standard is a vital step towards our expansion," said Executive Chairman, Raymond F. Akers Jr., Ph.D. "As well as demonstrating to future potential partners and distributors the Company's commitment to a quality management system, it may also help accelerate the process of gaining regulatory clearance for medical devices in certain countries, allowing us to get products to market faster," continued Dr. Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at www.akersbiosciences.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
CONTACT: For more information: Akers Biosciences, Inc. Raymond F. Akers, Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698 RedChip Companies, Inc. (US Investor Relations) Jon Cunningham Tel. +1 407 644 4256 x107 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel: +44 (0)20 7220 0500 Vigo Communications (UK Investor Relations) Ben Simons / Alexandra Roper Tel. +44 (0)20 7016 9570 Email. email@example.com
Source:Akers Biosciences, Inc.